Find Locations
For hours, walk-ins and appointments.Unable to load global navigation.
Acute Measles Panel, IgM Antibody and PCR
CPT:
86765; 87798
|
|
|
86765; 87798 |
Synonyms
Rubeola
Test Includes
Measles (Rubeola) Antibodies, IgM and Measles (Rubeola), PCR, Swab
Specimen Requirements
Specimen
Serum and throat or NP swab
Volume
1 mL serum and 1 swab
Minimum Volume
0.5 mL serum and 1 swab (Note: This volume does not allow for repeat testing.)
Container
Serum: gel-barrier tube, red-top tube or transfer tube
Swab: Viral Transport Media (VTM) or Universal Transport Media (UTM)
Collection
Serum: If tube other than a gel-barrier tube is used, transfer serum to a plastic transport tube.
Swab: Throat specimen (preferred): Collect the specimen by swabbing the posterior pharynx. Nasopharyngeal swab: Collect the NP swab using standard techniques.
Storage Instructions
Refrigerate.
Stability Requirements
| Temperature | Period |
|---|---|
| Room temperature | Unstable |
| Refrigerated | Serum: 7 days Swab: 7 days |
| Frozen | Serum: 6 months Swab: 14 days |
Causes for Rejection
Improperly submitted specimens; grossly hemolyzed, lipemic and icteric samples; heat-inactivated samples; samples with visible particulate matter or gross bacterial contamination; specimen not received in an approved VTM/UTM; swabs received in Liquid Amies (E-Swabs) or other bacterial swabs; specimens received without a swab; grossly leaking specimens; specimens received outside the stated stability
Test Details
Use
This test is used as a guideline-aligned laboratory diagnosis of acute measles virus infection in patients presenting with febrile rash illness and clinically compatible measles symptoms.
Limitations
A negative test does not rule out infection with measles virus. Results should be interpreted in conjunction with clinical finding.
The absence of IgM-class antibodies suggests lack of an acute phase infection with measles virus. However, serology may be negative for IgM-class antibodies in early disease, and results should be interpreted in the context of clinical findings.
Testing for IgM-class antibodies to measles should be limited to patients with clinically compatible disease. Specimens should be collected as soon as possible after the development of rash to maximize the sensitivity of measles RNA detection.
Improperly collected samples may result in false negative results.
PCR assays may be impacted by viral variants and may result in reduced sensitivity or false negative results.
The Measles PCR was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
|
A negative test does not rule out infection with measles virus. Results should be interpreted in conjunction with clinical finding. The absence of IgM-class antibodies suggests lack of an acute phase infection with measles virus. However, serology may be negative for IgM-class antibodies in early disease, and results should be interpreted in the context of clinical findings. Testing for IgM-class antibodies to measles should be limited to patients with clinically compatible disease. Specimens should be collected as soon as possible after the development of rash to maximize the sensitivity of measles RNA detection. Improperly collected samples may result in false negative results. PCR assays may be impacted by viral variants and may result in reduced sensitivity or false negative results. The Measles PCR was developed and its performance characteristics determined by Labcorp. It has not been |
|
A negative test does not rule out infection with measles virus. Results should be interpreted in conjunction with clinical finding. The absence of IgM-class antibodies suggests lack of an acute phase infection with measles virus. However, serology may be negative for IgM-class antibodies in early disease, and results should be interpreted in the context of clinical findings. Testing for IgM-class antibodies to measles should be limited to patients with clinically compatible disease. Specimens should be collected as soon as possible after the development of rash to maximize the sensitivity of measles RNA detection. Improperly collected samples may result in false negative results. PCR assays may be impacted by viral variants and may result in reduced sensitivity or false negative results. The Measles PCR was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administratio been cleared or approved by the Food and Drug Administration. |
Methodology
Chemiluminescence immunoassay (CLIA) and Polymerase Chain Reaction (PCR)
References
Clinical Overview of Measles. Centers for Disease Control and Prevention website: https://www.cdc.gov/measles/hcp/clinical-overview/index.html#cdc_clinical_overview_test_dia-diagnosis-and-laboratory-testing. Updated July 15, 2024. Accessed October 2024.
|
Clinical Overview of Meas |
|
Clinical Overview of Measles. Centers for Disease Control and Prevention website: https://www.cdc.gov/measles/hcp/clinical-overview/index.html#cdc_clinical_overview_test_dia-diagnosis-and-laboratory-testing. Updated July 15, 2024. Accessed October 2024. |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf